AGL

What Is the Overall Sentiment on agilon health inc. (AGL) Shares?

This afternoon we watched agilon health inc. drop -2.6% to a price of $16.89 per share. The large-cap Medical Distribution company is now trading -43.47% below its average target price of $29.88. Analysts have set target prices ranging from $22.5 to $41.0 per share for agilon health inc., and have given the stock an average rating of buy.

The stock has an unusually large proportion of its shares sold short at 27.9%, and a short ratio of 6.81. Since 1.09% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 106.1% of agilon health inc.'s shares being owned by this investor type.

Institutions Invested in agilon health inc.

Date Reported Holder Percentage Shares Value
2023-03-31 Clayton, Dubilier & Rice, LLC 47% 194,611,308 $3,286,984,873
2023-03-31 FMR, LLC 13% 54,656,726 $923,152,068
2023-03-31 Capital World Investors 10% 42,435,971 $716,743,524
2023-03-31 Morgan Stanley 9% 36,617,578 $618,470,870
2023-03-31 Wellington Management Group, LLP 5% 20,346,055 $343,644,856
2023-03-31 Vanguard Group, Inc. (The) 5% 19,236,251 $324,900,267
2023-03-31 Capital Research Global Investors 3% 13,043,536 $220,305,315
2023-03-31 Blackrock Inc. 2% 8,721,918 $147,313,189
2023-03-31 Rock Springs Capital Management, LP 2% 7,882,500 $133,135,420
2023-03-31 Durable Capital Partners Lp 1% 5,503,139 $92,948,014

Besides an analyst consensus of strong upside potential, other market factors point to there being mixed market sentiment on agilon health inc..

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS